MolDx Program
High payment rates for tests for rare disorders in regions covered by two Medicare Administrative Contractors could spark debate about genetic testing fraud.
Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests
Tests like MDxHealth's SelectMDx, Bio-Techne's ExoDx Prostate, and various PSA scoring algorithms would be reimbursed if they pass a technical assessment.
Four Years Into Foundational LCDs, Broader Reimbursement Coverage a Mixed Bag, Stakeholders Say
Premium
Palmetto GBA has expanded its decisions to cover classes of tests, rather than just one test, a move welcomed by most, but not all, of the industry.
Qlucore Raises SEK 30M as it Looks Toward IPO
The Swedish bioinformatics firm sees its greatest growth potential in precision cancer diagnostics as it prepares to go public in the next 12 months.
Natera Receives LCD From Palmetto for Signatera MRD Test in Colorectal Cancer Patients
The Medicare Administrative Contractor will cover ctDNA tests if the patient has a personal history of colorectal cancer.